Neuraura
Calgary
About Neuraura
Neuraura is leveraging their proprietary micro-electrodes to transform women’s reproductive and metabolic health with a wearable bioelectronic device for the treatment of PCOS. Neuraura is bringing to market the first effective, widely accessible treatment for PCOS as an over-the-counter, affordable device that augments the body's natural processes rather than just masking the symptoms. Neuraura is entering the market through an initial application in (pelvic) pain leveraging a predicate regulatory code (NUH) under an FDA 510(k) pathway. Once in market, Neuraura will escalate the device claims to the treatment of insulin resistance and other aspects of PCOS, leveraging targeted small-scale clinical studies as well as user data. Longer term, we are exploring a premium, reimbursed device for the treatment of pre-diabetes and diabetes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $763.8K
- Funding stage: Seed
- Last round: Grant (Mar 2025)
- Website: neuraura.com
- Phone: +1 (403)-3050082
Industries & Categories
Medical Device
Social Profiles
Canonical: https://fsome.com/organization/neuraura-140803 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.